Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Biol Macromol ; 164: 1321-1327, 2020 Dec 01.
Article in English | MEDLINE | ID: mdl-32698065

ABSTRACT

Reteplase is a deleted variant of human tissue plasminogen activator with a complex structure containing nine disulfide bonds. Reteplase is expressed as inclusion bodies in Escherichia coli and needs the additional step of refolding for activation. In this study an experimental design was performed to find the optimal refolding condition for reteplase. The influence of 14 chemical additives was assessed by one factor at a time method and then Taguchi design followed by response surface methodology was employed to find compounds with most significant effects on reteplase refolding and their optimum concentration. We found that 0.13 M histidine, 1.64 M methionine, 0.33 M cysteine, and 0.34 M arginine in addition to the GSH/GSSG is the optimal condition for refolding of reteplase. We also investigated the refolding yield for inclusion bodies obtained from different E. coli strains and found that BL21 (DE3) has the best recovery yield in comparison to Rosetta-gami and Shuffle T7.


Subject(s)
Escherichia coli/metabolism , Protein Refolding , Tissue Plasminogen Activator/chemistry , Arginine/chemistry , Cysteine/chemistry , Disulfides , Freezing , Glutathione/chemistry , Histidine/chemistry , Humans , Inclusion Bodies , Methionine/chemistry , Protein Denaturation , Recombinant Proteins/chemistry
2.
Neuroscience ; 388: 405-417, 2018 09 15.
Article in English | MEDLINE | ID: mdl-30102955

ABSTRACT

Alzheimer's disease (AD) is a debilitating neurodegenerative disease, characterized by extracellular deposition of senile plaques, mostly amyloid ß-protein (Aß) and neuronal loss. The neuroprotective effects of erythropoietin (EPO) have been reported in some models of neurodegenerative disease, but because of its hematopoietic side effects, its derivatives lacking hematopoietic bioactivity is recommended. In this study, the neuroprotective effects of carbamylated erythropoietin-Fc (CEPO-Fc) against beta amyloid-induced memory deficit were evaluated. Adult male Wistar rats weighing 250-300 g were bilaterally cannulated into CA1. Aß25-35 was administered intrahippocampally for 4 consecutive days (5 µg/2.5 µL/each side/day). CEPO-Fc (500 or 5000 IU) was injected intraperitoneally during days 4-9. Learning and memory performance of rats was assessed on days 10-13 using Morris Water Maze, then hippocampi were isolated and the amount of activated forms of hippocampal MAPKs' subfamily, Akt/GSK-3ß and MMP-2 were analyzed using Western blot. From the behavioral results, it was revealed that CEPO-Fc treatment in both 500 and 5000 IU significantly reversed Aß-induced learning and memory deterioration. From the molecular analysis, an increment of MAPKs and MMP-2 activity and an imbalance in Akt/GSK-3ß signaling after Aß25-35 administration was observed. CEPO-Fc treatment prevented the elevation of hippocampal of P38, ERK, MMP-2 activity and also Akt/GSK-3ß signaling impairment induced by Aß25-35 but it had no effect on JNK. It seems that CEPO-Fc prevents Aß-induced learning and memory deterioration, and also modulates hippocampal MAPKs, Akt/GSK-3ß and MMP-2 activity. This study suggests that CEPO-Fc can be considered as a potential therapeutic strategy for memory deficits like AD.


Subject(s)
Amyloid beta-Peptides/metabolism , Erythropoietin/pharmacology , Hippocampus/drug effects , Immunoglobulin Fc Fragments/genetics , Memory Disorders/drug therapy , Neuroprotective Agents/pharmacology , Nootropic Agents/pharmacology , Peptide Fragments/metabolism , Recombinant Fusion Proteins/pharmacology , Alzheimer Disease/drug therapy , Amyloid beta-Peptides/toxicity , Animals , Disease Models, Animal , Dose-Response Relationship, Drug , Erythropoietin/genetics , Glycogen Synthase Kinase 3 beta/metabolism , Hippocampus/metabolism , Hippocampus/pathology , Male , Matrix Metalloproteinase 2/metabolism , Maze Learning/drug effects , Maze Learning/physiology , Memory/drug effects , Memory/physiology , Memory Disorders/metabolism , Memory Disorders/pathology , Peptide Fragments/toxicity , Proto-Oncogene Proteins c-akt/metabolism , Rats, Wistar , Recombinant Fusion Proteins/genetics , Signal Transduction/drug effects
3.
Protein Expr Purif ; 151: 18-22, 2018 11.
Article in English | MEDLINE | ID: mdl-29775664

ABSTRACT

Reteplase is a third generation tissue plasminogen activator (tPA) with a modified structure and prolonged half-life in comparison to native tPA. As a non-glycosylated protein, reteplase is expressed in Escherichia coli. Due to presence of several disulfide bonds, high level production of reteplase is complicated and needs extra steps for conversion to biologically active form. Auto-induction represents a method for high-yield growth of bacterial cells and higher expression of recombinant proteins. Here we have tried to optimize the auto-induction procedure for soluble and active expression of reteplase in E. coli. Results showed that using auto-induction strategy at 37 °C, Rosetta-gami (DE3) had the highest level of active and soluble reteplase production in comparison to E. coli strains BL21 (DE3), and Shuffel T7. Temperature dominantly affected the level of active reteplase production. Decreasing the temperature to 25 and 18 °C increased the level of active reteplase by 20 and 60%, respectively. The composition of auto-induction medium also dramatically changed the active production of reteplase in cytoplasm. Using higher enriched auto-induction medium, super broth base including trace elements, significantly increased biologically active reteplase by 30%. It is demonstrated here that auto-induction is a powerful method for expression of biologically active reteplase in oxidative cytoplasm of Rosetta-gami. Optimizing expression condition by decreasing temperature and using an enriched auto-induction medium resulted in at least three times higher level of active reteplase production. Production of correctly folded and active reteplase in spite of its complex structure helps for removal of inefficient and cumbersome step of refolding.


Subject(s)
Escherichia coli/metabolism , Tissue Plasminogen Activator/biosynthesis , Cytoplasm/metabolism , Escherichia coli/genetics , Gene Expression Regulation , Protein Conformation , Protein Folding , Recombinant Proteins/biosynthesis
4.
Apoptosis ; 20(3): 298-309, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25451011

ABSTRACT

Parkinson's disease (PD) is the world's second most common dementia, which the drugs available for its treatment have not had effects beyond slowing the disease process. Recently nanotechnology has induced the chance for designing and manufacturing new medicines for neurodegenerative disease. It is demonstrated that by tuning the size of a nanoparticle, the physiological effect of the nanoparticle can be controlled. Using novel nanochelating technology, three nano complexes: Pas (150 nm), Paf (100 nm) and Pac (40 nm) were designed and in the present study their neuroprotective effects were evaluated in PC12 cells treated with 1-methyl-4-phenyl-pyridine ion (MPP (+)). PC12 cells were pre-treated with the Pas, Paf or Pac nano complexes, then they were subjected to 10 µM MPP (+). Subsequently, cell viability, intracellular free Calcium and reactive oxygen species (ROS) levels, mitochondrial membrane potential, catalase (CAT) and superoxide dismutase (SOD) activity, Glutathione (GSH) and malondialdehyde (MDA) levels and Caspase 3 expression were evaluated. All three nano complexes, especially Pac, were able to increase cell viability, SOD and CAT activity, decreased Caspase 3 expression and prevented the generation of ROS and the loss of mitochondrial membrane potential caused by MPP(+). Pre-treatment with Pac and Paf nano complexes lead to a decrease of intracellular free Calcium, but Pas nano complex could not decrease it. Only Pac nano complex decreased MDA levels and other nano complexes could not change this parameter compared to MPP(+) treated cells. Hence according to the results, all nanochelating based nano complexes induced neuroprotective effects in an experimental model of PD, but the smallest nano complex, Pac, showed the best results.


Subject(s)
Glutarates/pharmacology , Iron Chelating Agents/pharmacology , Neuroprotective Agents/pharmacology , Reactive Oxygen Species/antagonists & inhibitors , Animals , Apoptosis/drug effects , Calcium/metabolism , Caspase 3/metabolism , Catalase/metabolism , Cell Survival/drug effects , Glutarates/chemical synthesis , Glutathione/metabolism , Iron Chelating Agents/chemical synthesis , Malondialdehyde/antagonists & inhibitors , Malondialdehyde/metabolism , Membrane Potential, Mitochondrial/drug effects , Mitochondria/drug effects , Mitochondria/metabolism , Nanoparticles/chemistry , Nanoparticles/ultrastructure , Neuroprotective Agents/chemical synthesis , PC12 Cells , Piperidines/antagonists & inhibitors , Piperidines/pharmacology , Polymerization , Pyrazoles/antagonists & inhibitors , Pyrazoles/pharmacology , Rats , Reactive Oxygen Species/agonists , Reactive Oxygen Species/metabolism , Superoxide Dismutase/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...